- 1 Adjusted booster schedules disperse age-dependent differences in antibody titers
- 2 benefitting risk populations
- Update to: Age-dependent Immune Response to the BioNTech/Pfizer BNT162b2
- 4 Coronavirus Disease 2019 Vaccination
- 5 Lisa Müller^{1*±}, Marcel Andrée^{1*}, Wiebke Moskorz^{1*}, Ingo Drexler¹, Sandra Hauka¹, Johannes
- Ptok¹, Lara Walotka¹, Ramona Grothmann¹, Jonas Hillebrandt^{1, 2}, Anastasia Ritchie¹, Laura
- 7 Peter¹, Andreas Walker¹, Jörg Timm¹, Ortwin Adams^{1#}, Heiner Schaal^{1#}
- ¹ Institute of Virology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine
- 10 University Düsseldorf, Düsseldorf, Germany.
- ² Department of Nephrology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine
- 12 University Düsseldorf, Düsseldorf, Germany.
- 14 * contributed equally
- 15 # contributed equally
- \pm = corresponding author: Lisa.Mueller@uni-duesseldorf.de
- 18 Abstract

13

17

24

- 19 We provide follow-up data on the humoral immune response after COVID-19 vaccinations of
- a cohort aged below 60 and over 80 years. While anti-SARS-CoV-2 spike-specific IgG and
- 21 neutralization capacity waned rapidly after initial vaccination, additional boosters highly
- 22 benefitted humoral immune responses including neutralization of Omikron variants in the
- 23 elderly cohort.
- 25 Keywords
- 26 SARS-CoV-2; COVID-19; neutralizing antibodies; vaccination; humoral immune response;
- 27 longitudinal study

Introduction

28

29 From the onset of the SARS-CoV-2 pandemic in 2019, it quickly became clear that only 30 prophylactic immunization offered a way out of this global health crisis [1, 2]. In the following 31 year 2020, several manufacturers received emergency use authorization for their vaccines 32 against SARS-CoV-2. This included the novel class of mRNA vaccines, Comirnaty 33 (BioNTech/Pfizer) and Spikevax/mRNA-1273 (Moderna) [3, 4]. 34 In Germany and other countries, immunization schedules were rolled out at the end of 35 December 2020, prioritizing risk populations including immunocompromised and elderly 36 individuals [5]. With mRNA vaccines being the first of their kind, vaccinated risk populations 37 were in the focus of monitoring studies to evaluate the magnitude and quality of the immune 38 response to these vaccines [6, 7]. While initially, both mRNA formulations were designed as 39 "prime and boost" immunizations, several studies quickly pointed out the potential necessity 40 of at least a third vaccination, especially for populations with a generally reduced or short 41 lived humoral immune response [2, 8]. 42 With the emergence of more variants of concern such the currently predominant Omikron 43 variants which again caused a sharp surge in cases worldwide, the necessity of adjusted 44 vaccination schedules became more evident. Therefore, less than a year after the first vaccination campaigns started, several countries began their additional booster campaigns. 45 46 However, the combination of increasing case numbers and both, hetero- and homologous 47 booster vaccinations, predominantly using mRNA vaccines, has led to a complex mixture of 48 SARS-CoV-2-specific immunological profiles throughout the population. 49 Early in 2021, we performed a cohort study with two distinct age groups, vaccinees below 60 50 and above 80 years [9]. Here, we present a follow up of this vaccinee cohort. We revisited 51 the study cohort half a year and one year after their initial prime and boost vaccination. We 52 monitored the cohort for their total anti-SARS-CoV-2 spike-specific and nucleocapsid-specific 53 immune response as well as the magnitude of the neutralizing antibody response. Now that 54 Omikron is the most prevalent variant, we also included the neutralizing antibody response to 55 the Omikron BA.1 and BA.5. The follow-up of this cohort provides an important snapshot of

56

current immunological profiles.

Results

58

59 Participants were volunteers from the SBK nursing home in Cologne, Germany who 60 participated in both blood samplings for first part of the study (blood collection BC#1 and 61 BC#2, analyzed in Müller et. al., 2021 [9]) and in both follow-ups (blood collection BC#3 and BC#4) and gave informed consent (n = 84). They received their 1st vaccination with the 62 BioNTech/Pfizer vaccine at the end of December 2020 and their 2nd in late January 2021. All 63 individuals received their 3rd vaccination (97.7% BioNTech, 2.3% Moderna) between 64 65 September and November 2021. Additionally, 39 (46.4 %) of the participants received a 4th 66 vaccination in early February 2022 (100% BioNTech), 8 of the younger vaccinees, 31 of the 67 elderly. 68 Blood samples were analyzed for anti-SARS-CoV-2 nucleocapsid-specific (Abbott) and 69 spike-specific (Euroimmun) IgG titers and neutralizing SARS-CoV-2 antibodies against B.1 70 WT Omikron BA.1 (EPI_ISL_425126), (EPI_ISL_12813299.1) and BA.5 (EPI_ISL_14167576) isolates about 6- and 12-months (BC#3 and BC#4) after their first 71 72 vaccination to screen for age-related differences in the longevity of the humoral immune 73 response and the induction of the antibody response post booster-vaccinations. Participants 74 who reported an infection six months prior to the second follow-up (n =20) were analyzed 75 separately. This resulted in a final cohort of 64 vaccinated individuals (28 younger, 36 76 elderly). 77 At the first follow-up blood collection (BC#3) six months after their first vaccination, the 78 quantitative SARS-CoV-2 spike-specific IgG titers again differed significantly between the 79 two groups (p = 0.0435). For the group of elderly vaccinees, the mean IgG titer was 99.98 80 BAU/mL, ranging from 3.45 to 1111.0 BAU/mL. In this group, 41.6% of the tested individuals 81 had titers below cut-off (>35.2 BAU/mL). In the younger cohort, IgG titers ranged from 84.3 to 82 823.5 BAU/ml with a mean of 231.6 BAU/ml with no participants testing below cut-off (Figure 83 1A). At the second follow-up (BC#4) more than one year after the initial vaccination schedules, all participants had received a 3rd vaccination. Furthermore, 86% (n= 31) of the 84 elderly participants received a 4th vaccination, while only 28% (n = 8) of the younger 85 86 participants received the additional booster. At this blood collection (BC#4), SARS-CoV-2 87 spike-specific IgG titers were comparable between the age groups. Interestingly, the mean 88 SARS-CoV-2 spike-specific IgG titer in the group of elderly vaccinees was two-fold higher 89 (3337 BAU/mL) than for younger vaccinees (1663 BAU/mL) and no participant tested below 90 cut-off. However, titers ranged wider in the former group (68.0 - 10800 BAU/mL) than in the 91 latter (300 – 6950 BAU/mL).

92 Furthermore, we compared the time-dependent progress of the neutralization capacity 93

against a SARS-CoV-2 B.1 WT isolate between the age groups (Figure 1B). At the first

95 96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111112

113

114

115

116

117

118

119

120

121

122

follow-up (BC#3), the median neutralization titer (MNT) in the group of elderly participants drastically decreased to 0. After the elderly participants received their 3rd and 4th vaccination (BC#4), however, the MNT for the group of elderly participants was 640. For the group of younger vaccinees, MNT were significantly higher compared to the elderly. At the first followup (BC#3), median neutralization capacity against the B.1 WT isolate in this group was decreased to 20. At the one-year follow-up blood collection (BC#4), the MNT in the group of younger vaccinees was 320. The neutralization capacity determined by MNT was significantly decreased against both Omikron variants (BA.1 and BA.5) in both groups as compared to the B.1 WT. The MNT against Omikron BA.1 in the group of elderly participants was 160, against BA.5 it was decreased to 20 compared to 640 against the WT. Younger vaccinees showed an MNT of 40 against BA.1 and 10 against BA.5 compared to 320 against the WT isolate (Figure 1C). Furthermore, we separately analyzed the group of vaccinated convalescent participants (n = 20) compared to the overall vaccinated cohort (n = 64). The 20 convalescent participants (10 younger and 10 older vaccinees), reported an infection confirmed by PCR within the past six months prior to the second follow-up blood collection, 9 were infected in a community outbreak in early February 2022. A comparison of overall anti-SARS-CoV-2 spike-specific IgG titers showed significantly higher titers (p <0.0001) in the group of convalescent participants with a mean titer of 8560 BAU/mL compared to 2605 BAU/mL in the vaccinated cohort. It is of note that only 6 of 20 convalescent participants had anti-SARS-CoV-2 nucleocapsid-specific titers considered positive (Figure 1D). In this cohort, we also analyzed neutralizing antibodies and compared the WT and Omikron titers against the vaccinated cohort. In line with overall anti-SARS-CoV-2 spike-specific IgG levels, the convalescent cohort displayed significantly higher neutralizing antibody levels against WT and both Omikron isolates. However, despite the majority being infected with Omikron during the community outbreak in February 2022, Omikron neutralization titers were still lower than WT titers (Figure 1E).

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151152

153

154

155

156

157

Discussion We present the follow-up analysis of the SARS-CoV-2-specific antibody response to the BioNTech/Pfizer prime/boost vaccination of a cohort consisting of two age groups half a year and one year after their first COVID-19-vaccination. Both mRNA vaccinations that received emergency approval in late 2020 were initially designed as "prime/boost" vaccination schedules, however, longitudinal effects of the vaccinations were still to be determined. While it is evident that prophylactic immunizations decreased the pandemic burden and positively influenced the development of hospitalization and death rates [10], various studies pointed out potential limitations of the COVID-19vaccinations in specific sub-cohorts. These include immunocompromised patients, in particular organ transplant recipients [11] as well as elderly where the reduced induction of the humoral immune response after vaccination can likely be attributed to the effect of immunosenescence. In this follow-up study, we observed a drastic decrease of the anti-SARS-CoV-2 spikespecific IgG titer at the first follow-up blood collection six months after the cohort received their first vaccination. Especially in the group of elderly participants, these effects were even more pronounced, with more than a third of the elderly vaccinees testing below cut-off. This is in line with other studies which report a rapid antibody waning after prime/boost regimens [12]. It further underlines the necessity of strategies to overcome such limitations with additional boosters. Thus, shortly after the first follow-up, study participants received an asynchronous 3rd mRNA vaccination between September and November 2021, less than a year after their first vaccination. In early February 2022, Germany's vaccination commission recommended another booster for risk groups, so the majority of elderly participants received a 4th vaccination before the second follow-up blood collection. This fully dispersed the agedependent difference in mean IgG titers and neutralization capacity, although, as previously described, neutralization capacity against the Omikron BA.1 was drastically reduced, which was even more pronounced for BA.5 [13]. As shown in large cohort studies with participants aged over 60, the 4th vaccination resulted in elevated protection from severe illness, hospitalization and death and even short-lived protection from infection and thus, proved highly beneficial for risk groups [14, 15]. In the group of convalescent individuals, the humoral immune response was significantly increased compared to the vaccinated cohort, which is in line with previous results [16]. While a high number of convalescents was infected during an Omikron BA.1 outbreak shortly before the second follow-up blood collection, both Omikron neutralization titers were lower

than the neutralization titers against the B.1 WT, although neutralization titers against the WT were also significantly increased, suggesting a simultaneous induction of cross-reactive neutralizing antibodies against both variants [17]. Furthermore, anti-SARS-CoV-2 nucleocapsid-specific antibodies traditionally used as serological marker for natural infections were only detected in the minority of convalescent individuals. With increasing break-through infections in vaccinated individuals and data from large-scale cohort studies that showed the rapid decline of nucleocapsid specific antibodies especially in vaccinees [18], it seems highly likely that this serological marker will become even more unreliable with the rise of more complex immunological profiles.

169 Notes 170 Ethics Approval: The ethics committee of the Medical Faculty at the Heinrich-Heine 171 University Düsseldorf, Germany (study no. 2021-1287), approved the study. 172 Financial support. This work was supported by Stiftung für Altersforschung, Düsseldorf [to 173 H.S., L.W.], Jürgen Manchot foundation [to H.S., I.D. L.M., L.W., A.R., J.T., R.G.], by 174 research funding from Deutsche Forschungsgemeinschaft (DFG, German Research 175 Foundation) grant GK1949/2 and project number 452147069 [to I.D.], by the Ministry of 176 Labour, Health and Social Affairs of North-Rhine Westphalia (CPS-1-1A), by the Federal 177 Ministry of Education and Research (01KX2021) and by the Forschungskommission of the 178 Medical Faculty, Heinrich-Heine-Universität Düsseldorf [to H.S., J.P., J.H.] 179 Acknowledgments. The authors thank the members of Sozial Betriebe Köln, SBK for 180 excellent organization and support and for the opportunity to conduct this study and all helpers and the caregivers at SBK for their support at the blood collection days. We would 181 182 like to thank all volunteers at the SBK nursing home. We thank all members of the Virology 183 department and especially Yvonne Dickschen, Alexandra Graupner and Björn Wefers for 184 their excellent technical assistance. 185 Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. 186 187 Author contributions. Conceptualization: HS, OA, MA, LM, Formal analysis: WM, LM, 188 Investigation: All Authors; Writing – original draft preparation: HS, WM, OA, MA, LM, Writing 189 - review and editing: All Authors, Supervision: HS, OA, MA, LM 190 191 192 193

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215216

217


Figure 1: A Anti-SARS-CoV-2 spike specific antibody titers were determined for both age groups at each blood collection (BC#1 and BC#2 analyzed in Müller et. al., 2021 [9]). Antibody titers below the detection limit were set to 1.0. Boxes span the interquartile range; the line within each box denotes the median and whiskers indicate the 2.5 and 97.5 percentile values. **B** Neutralization titers of the two age groups were measured at each blood collection. Individuals who received an additional booster vaccination before the fourth blood collection are indicated with red symbols. C Comparison of the neutralization titers against a B.1 WT strain and Omikron BA.1 and BA.5 isolates between the two age groups at the fourth blood collection. D Comparison of anti-SARS-CoV-2 spike IgG titers between vaccinated only and vaccinated convalescent individuals at the fourth blood collection. Convalescent individuals with an anti-SARS-CoV-2 nucleocapsid-specific IgG titer considered positive are marked in yellow. E Comparison of the neutralization titers against B.1 WT and BA.1 and BA.5 Omikron isolates of the vaccinated only and vaccinated convalescent cohort. All data sets were tested with the Shapiro-Wilk test for normality. As most data sets did not show normal Gaussian distribution, parametric tests were performed. Two unpaired data sets (D) were compared by two-tailed Mann Whitney test. Comparison of two paired data sets (C and E) were done by two-tailed Wilcoxon matched-pairs signed rank test. For the comparison of antibody titers at different time points (A and B), tests within age groups were tested with two-tailed Friedman Test and comparison between age groups were tested with Kruskal Wallis Test (between), both followed by Dunn's multiple comparison test. All tests were performed using GraphPad Prism software Version 9.3.1.

References

218

- 219 1. Viana J, van Dorp CH, Nunes A, et al. Controlling the pandemic during the SARS-CoV-2 vaccination rollout. Nat Commun **2021**; 12(1): 3674.
- Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass
 Vaccination Setting. N Engl J Med 2021; 384(15): 1412-23.
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
 Vaccine. N Engl J Med 2021; 384(5): 403-16.
- 225 4. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med **2020**; 383(27): 2603-15.
- Cylus J, Panteli D, van Ginneken E. Who should be vaccinated first? Comparing vaccine
 prioritization strategies in Israel and European countries using the Covid-19 Health System
 Response Monitor. Isr J Health Policy Res 2021; 10(1): 16.
- Oliveira-Silva J, Reis T, Lopes C, et al. Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers. Vaccine **2022**; 40(4): 650-5.
- Swift MD, Breeher LE, Tande AJ, et al. Effectiveness of Messenger RNA Coronavirus Disease
 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2021; 73(6): e1376-e9.
- Wieske L, van Dam KPJ, Steenhuis M, et al. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol **2022**; 4(5): e338-e50.
- 9. Müller L, Andree M, Moskorz W, et al. Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **2021**; 73(11): 2065-72.
- 243 10. Moghadas SM, Vilches TN, Zhang K, et al. The impact of vaccination on COVID-19 outbreaks in the United States. medRxiv **2021**.
- Lee A, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. Bmj **2022**; 376: e068632.
- 247 12. Shrotri M, Navaratnam AMD, Nguyen V, et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet **2021**; 398(10298): 385-7.
- Hachmann NP, Miller J, Collier AY, et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med **2022**; 387(1): 86-8.
- 251 14. Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. N Engl J Med **2022**; 386(18): 1712-20.
- 253 15. Arbel R, Sergienko R, Friger M, et al. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. Nature medicine **2022**; 28(7): 1486-90.
- 256 16. Muller L, Andree M, Ostermann PN, et al. SARS-CoV-2 Infection in Fully Vaccinated Individuals of Old Age Strongly Boosts the Humoral Immune Response. Front Med (Lausanne) **2021**; 8: 746644.
- 259 17. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. medRxiv **2021**.
- 261 18. Krutikov M, Palmer T, Tut G, et al. Prevalence and duration of detectable SARS-CoV-2
 262 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of
 263 the pandemic (VIVALDI study): prospective cohort study in England. Lancet Healthy Longev
 264 2022; 3(1): e13-e21.

2022; 3(1): e13-e2.



BA.1 BA.5 WT

Vaccinated

BA.1 BA.5

Convalescent

WT BA.1 BA.5

< 60 years

WT BA.1 BA.5

> 80 years